Incorrect password
evipedia.ai Suggest Edit

Creatine for Health & Longevity

Evidence Review created on 05/03/2026 using AI4L / Opus 4.7

Also known as: Creatine Monohydrate, Creatine Hydrochloride, Creatine HCl, Creatine Ethyl Ester, Cr, CrM, N-(aminoiminomethyl)-N-methylglycine

Motivation

Creatine is a naturally occurring compound made by the body and obtained in small amounts from meat and fish, where it acts as a rapid energy buffer in muscle and brain cells. Creatine monohydrate is one of the most extensively studied dietary supplements, with hundreds of randomized trials spanning more than three decades.

Originally embraced by athletes for short-burst strength and power, creatine has more recently attracted attention for its potential effects on muscle preservation in aging and on cognition. Sports nutrition bodies have positioned it as a leading exercise-performance supplement, while emerging neuroscience research is exploring higher doses for the brain — though both perspectives sit within an evidence base shaped in part by interests with a stake in the outcome.

This review examines the clinical evidence, mechanisms, dosing strategies, and risks surrounding creatine, with attention to where the data are strongest, where they remain preliminary, and how they apply to longevity-oriented adults seeking to preserve muscle, cognition, and resilience with age.

Benefits - Risks - Protocol - Conclusion

A curated set of high-quality overviews on creatine from clinically oriented experts and longevity-focused publications.

Note: No dedicated Andrew Huberman (hubermanlab.com) episode or article focused on creatine could be confirmed via the search tools available; creatine is referenced in supplementation overviews on the platform but not as a primary topic. Only four qualifying high-level overview items are listed above to avoid padding the section with marginally relevant content or with sources whose publication type (e.g., systematic reviews) is excluded from this section.

Grokipedia

  • Creatine

    Encyclopedia entry covering creatine’s biochemistry, endogenous synthesis from arginine, glycine, and methionine, role in cellular bioenergetics via the phosphocreatine system, dietary sources, and its function as an osmolyte and modulator of ion channel activity.

Examine

  • Creatine

    Evidence-based summary of creatine supplementation with graded outcomes for strength, power, lean mass, cognition, and mental health, alongside a comparison of formulations (monohydrate vs. HCl vs. ethyl ester), dosing strategies, and a structured safety review including kidney function and the hair-loss/DHT (dihydrotestosterone, the potent androgen implicated in pattern hair loss) question.

ConsumerLab

  • Muscle & Workout Supplements (Creatine and BCAAs)

    ConsumerLab’s dedicated creatine hub aggregating independent product testing, clinical updates, and warnings, including documented identification of products containing unacceptable levels of creatinine and dicyandiamide breakdown impurities, with Top Picks selected based on quality, formulation, and value.

Systematic Reviews

A selection of recent systematic reviews and meta-analyses examining creatine across cognition, muscle, body composition, and renal safety domains.

Mechanism of Action

The primary mechanism of creatine is bioenergetic. Once absorbed, creatine is taken up into cells (predominantly skeletal muscle, but also brain, heart, and other tissues) via the SLC6A8 (the gene encoding the sodium- and chloride-dependent creatine transporter that moves creatine from blood into cells) creatine transporter, where it is phosphorylated by creatine kinase to phosphocreatine (PCr). PCr serves as a rapidly mobilizable reservoir of high-energy phosphate that regenerates ATP (adenosine triphosphate, the cellular energy currency) from ADP (adenosine diphosphate, the depleted form) during the first seconds of high-intensity work. Approximately 95% of body creatine is stored in skeletal muscle, with the remainder in brain, heart, and other tissues; daily turnover is roughly 1–2% of the total pool, requiring approximately 1–3 g/day of replacement from endogenous synthesis or diet.

Beyond the phosphagen system, creatine has additional effects relevant to longevity. It acts as a cell-volume osmolyte (an organic solute that helps cells regulate water content), supports satellite-cell activation and myonuclear addition implicated in muscle growth, modulates mitochondrial function and reactive oxygen species, and may attenuate inflammation. In the brain, creatine supports the same ATP buffering, with proposed effects on neuronal energy reserve, particularly during metabolic stress states such as sleep deprivation, hypoxia, and neurodegeneration.

Competing mechanistic interpretations exist regarding magnitude. Skeptics note that brain creatine increases modestly (typically 5–15%) at standard 3–5 g/day doses because the brain relies heavily on local endogenous synthesis and the blood-brain barrier limits transporter-mediated uptake — implying that meaningful neurological effects may require higher doses (10–20 g/day). Proponents counter that even modest increases at metabolically stressed sites may translate to functional benefit, supported by the larger cognitive effect sizes seen in older adults, vegetarians, and stressed states.

Pharmacokinetics: oral creatine monohydrate is approximately 99% bioavailable at standard 5–10 g doses; peak plasma concentration is reached at roughly 60 minutes; the elimination half-life from plasma is approximately 3 hours, but muscle saturation is the relevant pharmacodynamic endpoint and is achieved over 3–4 weeks of 3–5 g/day dosing or 5–7 days of a 20 g/day “loading” protocol. Unmetabolized creatine and the spontaneous degradation product creatinine are excreted renally.

Historical Context & Evolution

Creatine was first isolated in 1832 by French scientist Michel Eugène Chevreul from meat extract, with its connection to the phosphocreatine energy-buffering system established in the early-to-mid twentieth century. Through the 1980s, creatine was understood as a normal metabolite but had little practical application outside of clinical investigations of inborn creatine synthesis and transporter deficiencies.

The modern era began in the early 1990s when British researchers (notably Roger Harris and Eric Hultman) demonstrated that oral creatine monohydrate could meaningfully raise muscle creatine and phosphocreatine stores. Anecdotal reports surfaced that several gold-medal sprinters at the 1992 Barcelona Olympics had used creatine, and the supplement industry rapidly commercialized creatine monohydrate as an ergogenic aid. Hundreds of trials over the following decade established it as the most consistent performance supplement for high-intensity, repeated-effort exercise.

In parallel, researchers began investigating broader applications. By the 2000s and 2010s, work in older adults established meaningful effects on muscle preservation, while neurological investigations (initially in Huntington’s disease, ALS (amyotrophic lateral sclerosis, a progressive motor-neuron disease), and traumatic brain injury) began testing creatine in the brain. The 2017 ISSN position stand consolidated the safety record across more than two decades of use.

The most recent evolution is a shift in thinking about dose. Brain-imaging studies have shown that doses of 10–20 g/day produce substantially larger increases in brain phosphocreatine than the 3–5 g/day used in most muscle research, prompting trials in Alzheimer’s disease, depression, sleep deprivation, and perimenopause that use higher doses. Early findings — including the CABA pilot trial in Alzheimer’s — are consistent with the higher-dose hypothesis, though confirmatory trials are ongoing. The historical narrative has thus moved from “athletic supplement” to “broadly neuroactive metabolite with implications across the lifespan.”

Expected Benefits

A dedicated search of clinical sources, systematic reviews, and expert commentary was performed to identify the full benefit profile of creatine before this section was written.

High 🟩 🟩 🟩

Muscle Strength Gains with Resistance Training

Creatine supplementation combined with resistance training reliably increases muscle strength compared with resistance training alone. The effect is mediated by enhanced phosphocreatine availability for high-intensity contractions, plus indirect effects on training volume, satellite-cell activation, and cell hydration. Evidence base includes hundreds of RCTs and multiple meta-analyses across age groups, sexes, and training statuses; the 2024 Wang et al. meta-analysis in adults <50 years showed weighted mean improvements of 4.43 kg in upper-body and 11.35 kg in lower-body 1-rep-max strength versus placebo.

Magnitude: Approximately 5–15% greater strength gains versus resistance training alone; pooled WMDs (weighted mean differences, the average difference between treatment and placebo groups across pooled trials) of +4.4 kg upper-body and +11.4 kg lower-body 1RM (one-rep maximum, the heaviest load that can be lifted once) in adults under 50.

Increased Lean Body Mass

Creatine increases fat-free mass beyond what resistance training delivers alone. The mechanism combines acute intramuscular water retention (osmotic, occurring within days), enhanced training volume tolerance, and longer-term myofibrillar protein accretion. The 2024 Pashayee-Khamene meta-analysis of 143 RCTs reported a pooled +0.82 kg in fat-free mass and a small reduction (−0.28%) in body fat percentage. Effects are largest when supplementation is paired with resistance training and a maintenance dose is used.

Magnitude: Approximately +0.8 kg fat-free mass over training-control across RCTs of typical 8–12 week duration; larger effects with longer trials.

High-Intensity Exercise Performance

Creatine improves performance during repeated, short-duration, high-intensity efforts (sprinting, weightlifting sets, jumps, and intermittent sport activity). The mechanism is direct: faster phosphocreatine regeneration between efforts. The 2017 ISSN (International Society of Sports Nutrition) position stand identifies creatine monohydrate as the most effective ergogenic nutritional supplement currently available for increasing high-intensity exercise capacity; the ISSN is a sports-nutrition society whose membership and corporate sponsorship include parties with direct commercial interests in supplement sales, which is a relevant conflict of interest when weighing its consensus statements. Effects are smaller or absent for steady-state aerobic endurance.

Magnitude: 10–20% improvements in repeated sprint and high-intensity work output across pooled RCT data; minimal effect on continuous endurance.

Medium 🟩 🟩

Memory and Cognitive Performance in Older Adults ⚠️ Conflicted

Creatine appears to support memory performance in adults, with the largest signal in older individuals. The 2023 Prokopidis meta-analysis reported an overall SMD of 0.29 for memory in healthy adults, rising to SMD 0.88 in older adults aged 66–76. The 2024 Xu meta-analysis of 16 RCTs corroborated benefits on memory (SMD 0.31, GRADE moderate certainty), attention time, and processing speed. The conflict arises because effects on global cognition and executive function were not significant, individual trial sizes are small, and the optimal brain-targeted dose may exceed the 3–5 g/day used in most studies. Mechanism is bioenergetic, with brain phosphocreatine increases improving neuronal energy reserve under demand.

Magnitude: SMD ~0.3 overall on memory; SMD ~0.9 in adults 66–76 (a moderate-to-large effect by Cohen’s conventions).

Muscle Preservation and Function in Aging

In older adults, creatine combined with resistance training enhances gains in lean tissue mass and strength compared with resistance training alone, supporting functional independence and counteracting age-related sarcopenia. The 2021 Forbes et al. meta-analysis showed creatine augments these gains, with greater effects from higher-dose protocols (>5 g/day) and creatine taken on training days. The 2021 Dos Santos meta-analysis in older females found significant upper-body strength gains and benefit on lower-body strength when interventions ran ≥24 weeks.

Magnitude: Approximately +1.0–1.4 kg additional lean mass and 5–10% greater strength gains versus resistance training alone in older adults across pooled studies.

Low 🟩

Mood and Depressive Symptoms

Creatine has shown signals as an adjunct in major depressive disorder, including augmentation of SSRIs (selective serotonin reuptake inhibitors, the most commonly prescribed class of antidepressants) in early trials and a 2025 pilot finding that creatine added to cognitive behavioral therapy produced statistically greater improvement than CBT plus placebo, with more participants achieving remission. Mechanism is plausibly tied to brain energetics in regions implicated in depression. Evidence remains preliminary, with small samples and few replications.

Magnitude: In the CBT-augmentation pilot, the creatine arm moved from moderately severe to mild depression while placebo remained moderate; effect sizes not yet pooled across studies.

Cognitive Resilience to Sleep Deprivation

Acute high-dose creatine has been reported to attenuate the cognitive and mood decrements of sleep loss in small RCTs, plausibly by buffering brain ATP demand under stress. Mechanism aligns with the bioenergetic role of phosphocreatine. Evidence is limited to small short-duration studies.

Magnitude: Not quantified in available studies.

Bone Health Adjunct in Older Adults ⚠️ Conflicted

Creatine combined with long-duration resistance training has produced positive signals on bone mineral density and bone geometry in some trials of older adults, plausibly via greater training stimulus on bone. A 2018 brief meta-analysis (Forbes, Chilibeck, Candow) concluded that creatine plus resistance training did not produce greater bone mineral density gains than resistance training alone, though longer-duration trials (≥12 months) and certain bone subregions have shown more favorable signals. The conflict reflects heterogeneity in trial duration, the bone site assessed, and population sex/age.

Magnitude: Trial-level findings of small (1–2%) bone mineral density preservation effects in some 12-month studies, not consistent across pooled analyses.

Speculative 🟨

Neuroprotection in Neurodegenerative Disease

The CABA pilot trial in Alzheimer’s disease (20 g/day for 8 weeks) raised brain creatine ~11% and produced moderate improvements in working memory and executive function. Earlier trials in Huntington’s, Parkinson’s, and ALS have been mixed to negative for disease-modifying outcomes. The basis is mechanistic (mitochondrial bioenergetic support) and signal-level pilot evidence; controlled disease-modification trials are pending.

Cardiovascular and Metabolic Health

Mechanistic and small-trial evidence suggests creatine may modestly support muscle function in heart failure, possibly improve glycemic control as an adjunct to exercise, and reduce homocysteine in some contexts. A 2025 systematic review in heart failure (7 RCTs, 243 participants) found improved muscle strength and one positive 6-minute walk test result but no consistent effect on peak VO2 or ejection fraction. Evidence remains preliminary; effects are likely indirect (via exercise capacity).

Small RCTs in perimenopausal and postmenopausal women have reported improvements in reaction time, mood swings, and lipid profile with creatine. The basis is mechanistic and limited to early-stage trials in modest sample sizes, with the pivotal CONCRET-MENOPA trial (n=36) reporting medium-dose benefit on reaction time and serum lipids.

Benefit-Modifying Factors

  • Baseline dietary creatine intake: Vegetarians and vegans have lower muscle creatine stores (typically 20–25% lower) than omnivores and tend to show larger absolute responses to supplementation, particularly for cognitive measures. Heavy meat eaters may already be near saturation and see smaller marginal benefit.

  • Age: The cognitive and muscle-preservation benefits scale with age. The largest memory effect sizes in pooled analyses are in adults 66+, and the muscle-preservation case for creatine strengthens substantially after age 50 as sarcopenia risk rises.

  • Sex: Females typically have higher baseline intramuscular creatine concentrations (~70–80% of saturation versus ~60–70% in males) but may show comparable or larger relative benefit, particularly for cognitive endpoints. The 2024 Xu meta-analysis identified greater cognitive benefit in females; some strength meta-analyses show smaller hypertrophy responses, but the picture is heterogeneous.

  • Training stimulus: The hypertrophy and strength benefits of creatine require a concurrent resistance-training stimulus. Without training, body-composition effects are confined to small (water-mediated) changes in fat-free mass.

  • Pre-existing health conditions: Greater benefit is observed in conditions with bioenergetic compromise (heart failure, neurodegenerative disease, sarcopenia) than in healthy young athletes, where ceiling effects limit incremental gains.

  • SLC6A8 genetic variants: Rare loss-of-function variants in the X-linked creatine transporter cause cerebral creatine deficiency syndromes that do not respond to oral supplementation; very rare common-variant pharmacogenetic differences in transporter efficiency have been hypothesized but not clinically validated.

  • Baseline brain creatine: Individuals with lower baseline brain creatine (e.g., elderly, those under chronic metabolic stress, vegetarians) appear more likely to benefit cognitively from supplementation.

Potential Risks & Side Effects

A dedicated search of drug-reference sources and recent clinical literature (including pharmacovigilance reports, prescribing-information equivalents, drugs.com, and Mayo Clinic) was performed to ensure complete coverage of the side-effect profile.

High 🟥 🟥 🟥

Gastrointestinal Distress

Bloating, stomach discomfort, nausea, and diarrhea are the most commonly reported adverse effects, particularly with single doses exceeding 5–10 g and during loading-phase protocols (20 g/day split). Mechanism is osmotic: unabsorbed creatine in the intestinal lumen draws water and accelerates transit. A 2025 28-day medRxiv preprint reported GI symptoms in approximately 79% of participants overall, with higher incidence and severity in the loading-dose arm. Symptoms are typically mild, self-limiting, and largely avoidable by splitting doses and taking with food and adequate fluid.

Magnitude: GI symptoms reported in roughly 30–80% of users depending on dose protocol; severe symptoms uncommon.

Acute Weight Gain from Water Retention

Creatine causes a rapid 1–3 kg increase in body mass within the first 1–4 weeks of supplementation, predominantly from intramuscular water retention. Mechanism is osmotic — phosphocreatine increases intracellular osmolality, drawing water into muscle cells. The retention is not subcutaneous edema and does not affect appearance in most users, but it is relevant for weight-class athletes and may be misinterpreted as fat gain. Weight stabilizes after the initial loading phase.

Magnitude: Approximately +1–3 kg total body mass within 7–28 days; this represents intracellular fluid, not fat.

Medium 🟥 🟥

Spuriously Elevated Serum Creatinine

Creatine spontaneously degrades to creatinine, the metabolite measured in standard kidney-function panels. Supplementation can therefore raise serum creatinine and lower the calculated estimated glomerular filtration rate (eGFR, an estimate of how well the kidneys filter blood) without any actual change in kidney function. The 2019 de Souza E Silva meta-analysis confirmed measurable creatinine elevation but no evidence of renal injury. Clinical relevance: clinicians unfamiliar with creatine use may mistake the elevation for kidney disease; cystatin C (an alternative kidney filtration marker) is unaffected and can clarify the picture.

Magnitude: Serum creatinine typically rises 0.1–0.3 mg/dL with chronic supplementation; eGFR may decline by ~5–15 mL/min/1.73 m² without true filtration change.

Low 🟥

Muscle Cramping (Anecdotal) ⚠️ Conflicted

Anecdotal reports have linked creatine to muscle cramping, particularly in heat and during dehydration. Controlled studies have generally not found increased cramping incidence; some have found the opposite (creatine reduced cramps and dehydration markers). The conflict reflects that these reports come largely from athletes training in heat where multiple confounders apply. Mechanism would plausibly involve fluid shifts.

Magnitude: Not quantified in controlled studies; controlled trials suggest no excess risk over placebo.

Compartment Syndrome Risk During Heat Stress

Case reports and a few small studies have raised concern that creatine, by increasing intramuscular fluid, may exacerbate exertional compartment syndrome (a buildup of pressure in muscle compartments) under extreme exertion in heat. Evidence is limited to mechanistic plausibility and isolated reports. Severity, when it occurs, is high. Most relevant to military, occupational, and ultra-endurance settings rather than typical resistance training.

Magnitude: Not quantified in available studies.

Speculative 🟨

DHT Elevation and Hair Loss

A single 2009 South African RCT in rugby players reported a ~50% increase in dihydrotestosterone (DHT) with creatine, prompting concern about androgenic alopecia (pattern hair loss). The finding has not been replicated; a 2025 12-week RCT specifically examining this question found no change in raw DHT, no hair loss, and no adverse events. A large 2025 safety analysis of 685 studies in over 26,000 participants found side-effect rates equivalent to placebo. The basis remains a single unreplicated study; clinical hair-loss reports in users are not differentiable from background androgenetic alopecia rates.

Renal Damage in Pre-existing Kidney Disease

Concern that creatine could worsen pre-existing chronic kidney disease (CKD) is mechanistically plausible (additional load through filtration) and has been raised in case reports, but RCTs in patients with kidney disease have not demonstrated harm. The 2025 BMC Nephrology meta-analysis (Naeini et al.) found no evidence that creatine adversely affects kidney function. Despite this, caution is warranted in advanced CKD given limited data.

Risk-Modifying Factors

  • Pre-existing kidney disease: Individuals with established chronic kidney disease, particularly those at stage 3 or beyond (eGFR <60 mL/min/1.73 m²), should consult a nephrologist before supplementation given limited safety data in advanced CKD, even though current evidence does not show harm in healthy individuals or those with mild renal impairment.

  • Baseline biomarker levels: Baseline kidney-function markers shape risk interpretation: reduced baseline eGFR (e.g., <60 mL/min/1.73 m²) or elevated baseline serum creatinine signals greater need for monitoring, while a normal baseline panel (creatinine, eGFR, electrolytes) provides an anchor that distinguishes future creatine-induced creatinine elevation from genuine renal change. Baseline cystatin C is similarly useful in those with low or high muscle mass where standard creatinine is misleading.

  • Age (older adults): Older adults are more likely to take medications metabolized renally, more likely to have undiagnosed reduced kidney function, and more likely to have nuisance GI symptoms — all reasons to start at a lower dose without loading.

  • Sex (females): Females tend to have higher baseline intramuscular creatine and may achieve saturation more quickly; tolerability of higher (10–20 g) doses for cognitive applications appears similar to males in available trials.

  • Genetic variation in SLC6A8: Loss-of-function variants in the X-linked creatine transporter (rare) cause cerebral creatine deficiency that does not respond to standard supplementation; safety concerns are unrelated.

  • Concurrent diuretic, NSAID, or nephrotoxic drug use: Combinations that reduce renal perfusion or filtration capacity increase the importance of staying well-hydrated when supplementing creatine.

  • Bipolar disorder: Case reports describe manic switches in bipolar patients started on creatine, plausibly via brain bioenergetic effects on mood circuits; caution is warranted in this population.

  • Pregnancy and lactation: Although emerging maternal-fetal research is exploring creatine’s role in obstetric outcomes, supplementation during pregnancy and lactation has not been adequately studied for routine use.

  • Heat exposure and dehydration: Adequate hydration is important for any user; in extreme exertional-heat settings (military, fire service, ultra-endurance) the case for creatine should weigh the very rare compartment-syndrome and cramping reports.

Key Interactions & Contraindications

  • Caffeine — Caution, possibly attenuated effect: Co-ingestion of high-dose caffeine (≥5 mg/kg) with creatine has been suggested to blunt creatine’s ergogenic effect in some studies, though evidence is mixed. Mitigating action: separate timing of pre-workout caffeine and creatine doses if maximum performance is the goal; for general daily use, no separation is needed.

  • Nephrotoxic medications (aminoglycoside antibiotics, NSAIDs at chronic high doses, contrast agents) — Caution, monitor renal function: Concurrent use can theoretically compound any subclinical effect on the kidney; existing meta-analyses in healthy people show no creatine renal harm but baseline + interim renal monitoring is prudent.

  • Loop and thiazide diuretics (furosemide, hydrochlorothiazide) — Caution, monitor hydration: Increased dehydration risk; ensure adequate fluid intake.

  • Cimetidine, trimethoprim, probenecid — Monitor renal markers: These competitively inhibit tubular creatinine secretion and can independently elevate serum creatinine; the combination further confounds eGFR interpretation.

  • Metformin — Caution, monitor: Both metformin and creatine are renally cleared; in patients with impaired renal function, additive demand on the kidneys warrants monitoring.

  • Other ergogenic supplements with additive water-retention effects (beta-alanine, sodium bicarbonate, betaine) — No clinical concern but expected additive cell-volume effects: Often stacked with creatine intentionally; no contraindication.

  • Lithium — Monitor: Both compounds influence renal handling and water balance; clinically meaningful interactions have not been documented but caution is reasonable in psychiatric populations.

  • Antidepressants (SSRIs) — No clinical concern, monitor: Augmentation studies have generally shown additive benefit rather than interaction; no contraindication, though psychiatric supervision is appropriate when combining for mood indications.

  • Populations who should avoid creatine without medical supervision:

    • Stage 3+ chronic kidney disease (eGFR <60 mL/min/1.73 m²) or known kidney disease
    • Currently active or recently treated kidney stones
    • Bipolar disorder (history of mania or current mood instability)
    • Pregnancy and lactation (insufficient routine-use data)
    • Children and adolescents (use in this age group should be supervised; no general indication for healthy children)

Risk Mitigation Strategies

  • Skip the loading phase to reduce GI symptoms: Use a maintenance-only protocol (3–5 g/day) rather than a 20 g/day loading phase; muscle saturation is reached in approximately 3–4 weeks instead of 5–7 days, but with substantially lower GI side-effect rates and the same ultimate steady-state stores.

  • Split doses with food and fluid: If using doses >5 g/day, split into two or more administrations (e.g., 5 g morning and 5 g evening) taken with at least 250 mL of water and ideally with a meal. This mitigates osmotic GI symptoms.

  • Document baseline creatinine and obtain cystatin C if needed: To avoid future misinterpretation of supplementation-induced creatinine elevation as kidney disease, obtain a baseline serum creatinine and consider documenting cystatin C either at baseline or at any future point where eGFR appears reduced.

  • Choose a third-party-tested creatine monohydrate product: ConsumerLab and other testing has identified products with elevated creatinine and dicyandiamide breakdown impurities. Selecting a product with USP, NSF, Informed Sport, or ConsumerLab approval mitigates contamination and content-quality risk.

  • Maintain hydration, particularly in heat: A simple glass of water with each dose and routine fluid intake addresses the small theoretical risks of cramping and compartment syndrome that have been raised in heat-stress contexts.

  • Re-test eGFR with cystatin C if a clinician flags creatinine: If a routine clinic visit reports an unexpected eGFR drop on the standard creatinine-based equation, request a cystatin C measurement to disambiguate supplementation-related creatinine elevation from genuine renal change.

  • Reduce dose or pause if GI symptoms persist: If bloating or loose stools persist after 1–2 weeks of split-dose, with-food administration, reduce to 2–3 g/day or temporarily pause to confirm causation.

  • Avoid use in active mania or mood instability: Bipolar patients considering creatine for mood or cognition should do so under psychiatric supervision given case reports of manic switches.

Therapeutic Protocol

  • Standard maintenance dose: 3–5 g/day of creatine monohydrate, taken consistently and indefinitely. This protocol achieves muscle saturation in approximately 3–4 weeks and is the most extensively studied dose. Endorsed across the 2017 ISSN position stand and most longevity-oriented practitioners.

  • Higher dose for cognitive applications: 5–10 g/day for adults specifically targeting cognitive benefit, particularly those over 60 or with high cognitive load. Some experts (Rhonda Patrick, Darren Candow) take 10 g/day as a default; very-high-dose protocols (20 g/day) are used in active research settings (Alzheimer’s disease, sleep deprivation, perimenopause) with reasonable tolerability when split into two doses.

  • Optional loading phase: 0.3 g/kg/day (~20 g/day for a 70 kg adult), divided into 4 doses of 5 g for 5–7 days, followed by 3–5 g/day maintenance. Achieves saturation faster (~1 week) but with higher GI symptom rates. Most longevity-focused practitioners skip loading.

  • Form selection: Creatine monohydrate is the preferred form. Liquid creatine, creatine ethyl ester, and many “buffered” or “novel” creatine forms have either been shown to be inferior or have not demonstrated meaningful advantages over monohydrate in head-to-head comparisons. Creatine HCl has improved water solubility but no consistent functional superiority.

  • Best time of day: Timing does not meaningfully affect outcomes; consistency matters more than time of day. Some evidence suggests post-workout dosing alongside carbohydrate and protein modestly improves uptake, but the practical effect is minor. Select a time that supports adherence.

  • Half-life and dosing structure: The plasma half-life of creatine is approximately 3 hours, but the relevant pharmacodynamic endpoint is muscle phosphocreatine saturation, which has a much longer time constant. Once saturated, daily replacement of the ~1–2% turnover requires only 3–5 g/day; missed doses for a few days do not appreciably deplete stores.

  • Single vs. split doses: Single daily doses up to 5 g are well tolerated. Doses above 5 g/day should be split (e.g., 5 g twice daily) to reduce GI symptoms and improve absorption.

  • Genetic considerations: No common pharmacogenetic variants currently warrant differential dosing. Rare SLC6A8 loss-of-function (cerebral creatine deficiency) is not addressed by oral creatine. APOE4 (a variant of the apolipoprotein E gene linked to higher Alzheimer’s-disease risk), MTHFR (the gene for methylenetetrahydrofolate reductase, an enzyme in folate metabolism and methylation), COMT (catechol-O-methyltransferase, an enzyme that breaks down catecholamines such as dopamine), and other longevity-relevant variants do not modify standard protocols.

  • Sex differences in dosing: Females may saturate at slightly lower absolute doses given lower body mass; the 3–5 g/day maintenance dose is appropriate across sexes. Higher-dose cognitive protocols have been studied in mixed populations including women, with similar tolerability.

  • Age-related considerations: Older adults derive proportionally larger benefit from creatine plus resistance training. Start at 3 g/day for the first 1–2 weeks before titrating to 5 g/day to assess GI tolerance; consider 5–10 g/day if cognitive support is the primary goal.

  • Baseline biomarker considerations: Document baseline serum creatinine before initiation to prevent later confusion. No other baseline labs are required for healthy adults; CKD patients should have eGFR + cystatin C documented and a nephrology consult before initiation.

  • Pre-existing health conditions: Active mania or recent manic episodes (in bipolar disorder) and stage 3+ CKD warrant medical supervision. Most other chronic conditions (cardiovascular disease, type 2 diabetes, osteoarthritis) are not contraindications.

Discontinuation & Cycling

  • Designed for indefinite use: Creatine is intended for continuous, lifelong daily supplementation in most longevity contexts. Sustained muscle and brain phosphocreatine elevation is the goal, achieved only with consistent intake.

  • No withdrawal effects: Stopping creatine produces no withdrawal symptoms. Muscle creatine stores return to baseline over approximately 4–6 weeks; the body resumes endogenous synthesis (which is partially down-regulated during exogenous intake).

  • No tapering required: No tapering protocol is needed when discontinuing.

  • Cycling not recommended for efficacy: Unlike compounds where receptor down-regulation drives diminishing returns, creatine acts through saturable cellular pools. Cycling on/off does not improve efficacy and instead introduces saturation gaps. The 2017 ISSN position stand explicitly notes no benefit to cycling.

  • Brief breaks acceptable: Short pauses (vacation, illness, travel) are inconsequential; missed doses for up to 1–2 weeks have minimal impact on stores. Resumption returns stores to saturation within 3–4 weeks at maintenance dosing.

Sourcing and Quality

  • Choose creatine monohydrate as the form: Of all available formulations, creatine monohydrate has the strongest evidence base, highest bioavailability (~99%), and lowest cost per gram. There is no consistently demonstrated functional advantage to creatine HCl, ethyl ester, malate, citrate, magnesium chelate, or other variants.

  • Look for third-party testing: Independent verification (Informed Sport, NSF Certified for Sport, USP, ConsumerLab Approval) is the most reliable indicator of product purity. ConsumerLab testing has identified products with unacceptable levels of breakdown products (creatinine, dicyandiamide). Approved products typically contain ≥99.9% creatine with combined creatinine and dicyandiamide ≤0.1%.

  • Prefer Creapure-branded raw material where available: Creapure is the German-manufactured creatine monohydrate produced by AlzChem with a documented synthesis pathway and consistent purity record. Many reputable supplement brands disclose Creapure sourcing on their labels.

  • Powder is preferred over capsules for cost: Creatine monohydrate powder is among the cheapest supplements per effective dose; capsules add convenience but multiply the cost per gram. A 5 g maintenance dose typically costs <$0.10–0.30 in powder form.

  • Storage and stability: Creatine monohydrate powder is highly stable when kept dry. Once dissolved in water, creatine slowly converts to creatinine; pre-mixed liquids should be consumed within hours. Storage: cool, dry, sealed.

Practical Considerations

  • Time to effect: Strength and high-intensity performance benefits typically emerge within 2–4 weeks of consistent daily dosing (the time required for muscle phosphocreatine saturation). Cognitive benefits, where they occur, may take longer (4–8+ weeks) and may require higher doses. Acute weight gain (water) appears within the first week.

  • Common pitfalls: (1) Inconsistent daily dosing — saturation requires consistency; (2) loading-phase GI symptoms leading users to abandon the supplement when a maintenance-only protocol would have been better tolerated; (3) selecting expensive “novel” formulations when monohydrate is cheaper and better-evidenced; (4) interpreting initial water-mediated weight gain as fat gain; (5) clinicians or patients misreading creatine-related serum creatinine elevation as kidney disease.

  • Regulatory status: Creatine is regulated as a dietary supplement in the United States (under the 1994 DSHEA — Dietary Supplement Health and Education Act — framework) and in most other jurisdictions. It is not on the World Anti-Doping Agency (WADA) prohibited list and is permitted in essentially all competitive sport. EFSA (European Food Safety Authority) has issued positive opinions on creatine’s effect on physical performance in the EU.

  • Cost and accessibility: Creatine monohydrate is among the most affordable evidence-based supplements available; daily cost typically ranges $0.05–$0.50, even for high-quality third-party-tested powders. Widely available online and in retail; no prescription required.

Interaction with Foundational Habits

  • Sleep: Direct interaction is minimal — creatine does not appear to disrupt sleep at any dose, and no consistent timing recommendation is needed relative to sleep. Indirect: a small literature suggests creatine may attenuate the cognitive and mood deficits of sleep deprivation, plausibly via brain energetic buffering. Practical consideration: timing does not affect sleep, so dose at any preferred time.

  • Nutrition: Creatine has no known nutrient depletion concerns. It is partially obtained from meat and fish (~1 g per 200 g of meat), so vegetarians/vegans typically have lower baseline stores and may experience larger absolute responses. Co-ingestion with a carbohydrate + protein meal modestly enhances muscle uptake (insulin-mediated), though the practical effect is small. Practical consideration: take with a meal if convenient; vegetarians and vegans are particularly likely to benefit.

  • Exercise: Direct potentiating interaction with resistance training: nearly all of creatine’s body-composition and strength benefits require a concurrent resistance-training stimulus. The effects on aerobic endurance are minimal. Mechanism: enhanced phosphocreatine availability supports higher training quality and intensity. Practical consideration: pair creatine with structured resistance training 2–4 times per week for maximal benefit; on non-training days, continue daily dose to maintain saturation.

  • Stress management: Indirect interaction; creatine has not been shown to alter cortisol or HPA-axis (hypothalamic–pituitary–adrenal axis, the central stress-response system) function meaningfully. Some evidence suggests cognitive benefit under metabolic stress (sleep loss, intense cognitive demand). No specific timing recommendation around stress practices.

Monitoring Protocol & Defining Success

Baseline testing is recommended primarily to document the “pre-creatine” creatinine value, which prevents later confusion. Most other baseline labs are optional for healthy adults but useful for older adults or those with risk factors.

Ongoing monitoring should occur at baseline, at 3 months after initiation (especially if higher doses are used), and then annually as part of routine health assessment. There is no formal evidence-based cadence; this reflects practitioner-derived guidance.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum creatinine <1.1 mg/dL (women), <1.3 mg/dL (men); expect ~0.1–0.3 mg/dL elevation on creatine Baseline anchors interpretation of any future eGFR measurement Fasting not required; values rise with creatine supplementation independent of kidney function
Cystatin C 0.6–1.0 mg/L Alternative kidney filtration marker unaffected by creatine supplementation Useful when creatine-elevated creatinine causes confusion; not influenced by muscle mass or supplementation
eGFR (creatinine-based; CKD-EPI) ≥90 mL/min/1.73 m² (G1); ≥60 (G2) Standard kidney filtration estimate; will appear reduced on creatine Recalculate using cystatin C–based equation if a creatinine-based eGFR drop is reported
BUN 7–20 mg/dL Complementary marker of renal function and protein metabolism BUN = blood urea nitrogen, a nitrogenous waste-product marker. Modest elevations may occur with creatine; usually clinically insignificant in healthy individuals
Body mass Individual baseline; expect +1–3 kg in first month Documents the expected water-mediated weight increase Track over 4–8 weeks; stabilizes after initial saturation
Grip strength or 1-rep max Individual baseline Functional outcome of training plus creatine Most practical measure for older adults to track functional response
Total testosterone & DHT Total T 300–1000 ng/dL (men); DHT 30–85 ng/dL (men) Optional for men concerned about androgenic-alopecia narrative Best evidence shows no creatine effect on these values

Qualitative markers worth tracking subjectively:

  • Training quality and recovery (especially repeated-set capacity)
  • Subjective energy and cognitive sharpness, particularly under sleep deprivation
  • Memory and attention performance for those over 60
  • GI tolerance during initiation (bloating, loose stools)
  • Mood stability, especially in those using creatine for mood-related applications

Emerging Research

  • D3-Creatine Skeletal Muscle Trial in Older Adults (NCT06630949): A recruiting study (n=350) using deuterated D3-creatine to directly quantify skeletal muscle mass and turnover in aging, providing higher-precision data on age-related creatine kinetics than is achievable with bioelectrical impedance or DXA (dual-energy X-ray absorptiometry, an imaging method for body composition) based methods.

  • Creatine and Resistance Training in Mild Cognitive Impairment (NCT06948149): A 26-week 2x2 factorial RCT (n=200) using daily 0.10 g/kg creatine monohydrate with or without progressive resistance training in older adults with mild cognitive impairment, designed to test whether the combination produces additive benefit over either intervention alone for cognitive and physical function endpoints.

  • CABA-style Trials in Alzheimer’s Disease: Following the Smith et al., 2025 CABA pilot showing 11% increases in brain creatine and improvements in working memory after 8 weeks of 20 g/day, larger placebo-controlled efficacy trials are being designed to test disease-modifying or symptomatic effects in early Alzheimer’s disease.

  • Creatine + CBT for Depression: A 2025 pilot trial reported in the Peter Attia summary showed creatine added to cognitive behavioral therapy produced larger improvements in depression scores and more remissions than CBT alone — the basis for expected larger replication trials.

  • Higher-Dose Brain Creatine Studies: A growing body of magnetic resonance spectroscopy (MRS, a brain-imaging technique that quantifies metabolite concentrations such as creatine non-invasively) work and emerging neuroimaging research is testing whether 10–20 g/day produces meaningfully greater brain creatine elevations than the standard 3–5 g/day, which could re-anchor “longevity dose” guidance upward.

  • CONCRET-MENOPA and Menopausal Health: The CONCRET-MENOPA trial in perimenopausal and postmenopausal women reported reaction-time and lipid-profile improvements with 1,500 mg/day creatine HCl over 8 weeks; larger trials in this demographic are anticipated given the strong commercial and clinical interest in menopause-related interventions.

  • Areas Where Research Could Strengthen the Case: Larger long-duration RCTs in older adults using cognitive endpoints (especially with brain MRS) building on Prokopidis et al., 2023; adequately-powered Alzheimer’s disease efficacy trials extending the Smith et al., 2025 CABA pilot; replications of the depression-augmentation finding; and bone-health trials >12 months in postmenopausal women extending Forbes et al., 2021.

  • Areas Where Research Could Weaken the Case: Properly conducted long-duration safety surveillance in CKD populations beyond de Souza E Silva et al., 2019; replication or refutation of the bipolar manic-switch case reports; large pragmatic trials examining whether the clinical effect sizes pool as favorably as small-trial meta-analyses such as Pashayee-Khamene et al., 2024 suggest; and head-to-head comparisons against more potent muscle-preservation interventions (resistance training alone, anabolic strategies) in older adults.

Conclusion

Creatine is one of the most thoroughly studied dietary supplements in modern nutrition science, with decades of randomized trial evidence and a strong safety record. The strongest case is for adults engaged in resistance training: pooled data consistently show meaningful gains in muscle strength and lean tissue mass, with effects that translate to functional independence in older adults at risk of muscle loss.

A more recent body of evidence supports cognitive benefit, with the largest signals in older adults and metabolically stressed states. Memory effects appear robust in pooled analyses, while disease-modifying neurological effects remain preliminary. Mood, bone health, cardiovascular function, and menopausal symptoms have early supportive signals not yet confirmed in large trials.

Side effects are generally mild and dose-dependent, dominated by gastrointestinal symptoms during loading and a rise in measured kidney-filtration markers that does not reflect kidney injury. The kidney concern, hair-loss narrative, and other widely circulated worries are not supported by current pooled evidence, though caution remains appropriate in pre-existing kidney disease, bipolar disorder, and pregnancy.

A significant share of the evidence base — particularly the most enthusiastic position statements from sports-nutrition bodies — comes from researchers and organizations with ties to the supplement industry, which is a relevant conflict of interest when weighing the strongest claims, even though it does not negate the underlying randomized-trial signals.

For longevity-oriented adults willing to combine supplementation with resistance training and mindful of basic safety considerations, creatine offers a favorable risk-to-benefit profile across multiple age-relevant domains.

Top - Benefits - Risks - Protocol